[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1962

Flury Rabies Vaccine for Human Use

Author Affiliations

PEARL RIVER, N.Y.

From the Medical Research and Virology Sections, Lederle Laboratories Division, American Cyanamid Company, Pearl River, N.Y.

Arch Intern Med. 1962;110(5):754-757. doi:10.1001/archinte.1962.03620230200027
Abstract

While man is probably highly resistant to extraneural infection by the rabies virus, each year records the death of several persons after sustaining a wound inflicted by a rabid animal. While the infliction of the wound usually precedes the clinical signs of infection by a sufficiently long interval to institute prophylaxis, the recent report of Constantine1 raises the specter that mammals may become infected without the association of trauma. Moreover, prevention of the disease by conventional methods has failed sufficiently often to indicate the desirability of increasing the efficacy of available vaccines. Most of the vaccines currently in use in man contain mammalian nervous tissue which apparently has the potential of tissue-specific sensitization which is presumably the cause of demyelinating incidents in a small but frightening per cent of subjects who submit to the conventional Pasteur prophylaxis of rabies. Consequently, it seems desirable to develop vaccines which contain no

First Page Preview View Large
First page PDF preview
First page PDF preview
×